Inhibitors of BACE for treating alzheimer's disease: A fragment-based drug discovery story

Current Opinion in Chemical Biology

Volumn 17, Issue 3, 2013, Pages 320-328

  Stamford, Andrew ^a   Strickland, Corey ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA SECRETASE 1; BETA SECRETASE INHIBITOR;

ALZHEIMER DISEASE; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; PHARMACOPHORE; PROTEIN STRUCTURE; REVIEW; X RAY CRYSTALLOGRAPHY;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; DRUG DESIGN; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS;

EID: 84878886764     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2013.04.016     Document Type: Review

References (50)

1. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
2. Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011, 10:698-711.
3. Jonsson T., Atwal J.K., Steinberg S., Snaedal J., Jonsson P.V., Bjornsson S., Stefansson H., Sulem P., Gudbjartsson D., Maloney J., et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488:96-99.
4. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
5. Yan R.Q., Bienkowski M.J., Shuck M.E., Miao H.Y., Tory M.C., Pauley A.M., Brashler J.R., Stratman N.C., Mathews W.R., Buhl A.E., et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999, 402:533-537.
6. Sinha S., Anderson J.P., Barbour R., Basi G.S., Caccavello R., Davis D., Doan M., Dovey H.F., Frigon N., Hong J., et al. Purification and cloning of amyloid precursor protein beta secretase from human brain. Nature 1999, 402:537-540.
7. Hussain I., Powell D., Howlett D.R., Tew D.G., Meek T.D., Chapman C., Gloger I.S., Murphy K.E., Southan C.D., Ryan D.M., et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 1999, 14:419-427.
8. Lin X., Koelsch G., Wu S., Downs D., Dashti A., Tang J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA 2000, 97:1456-1460.
9. Roberds S.L., Anderson J., Basi G., Bienkowski M.J., Branstetter D.G., Chen K.S., Freedman S.B., Frigon N.L., Games D., Hu K., et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001, 10:1317-1324.
10. Stachel S.J. Progress toward the development of a viable BACE-1 inhibitor. Drug Dev Res 2009, 70:101-110.
11. Probst G., Xu Y.-Z Small-molecule BACE1 inhibitors: a patent literature review (2006-2011). Expert Opin Ther Patents 2012, 22:511-540.
12. Murray C.W., Callaghan O., Chessari G., Cleasby A., Congreve M., Frederickson M., Hartshorn M.J., McMenamin R., Patel S., Wallis N. Application of fragment screening by X-ray crystallography to β-secretase. J Med Chem 2007, 50:1116-1123.
13. Edwards P.D., Albert J.S., Sylvester M., Aharony D., Andisik D., Callaghan O., Campbell J.B., Carr R.A., Chessari G., Congreve M., et al. Application of fragment-based lead generation to the discovery of novel, cyclic amidine β-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J Med Chem 2007, 50:5912-5925.
14. Wang Y.-S., Strickland S., Voigt J.H., Kennedy M.E., Beyer B.M., Senior M.M., Smith E.M., Nechuta T.L., Madison V.S., Czarniecki M., et al. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel μM leads for the development of nM BACE-1 (β-site APP cleaving enzyme 1) inhibitors. J Med Chem 2010, 53:942-950.
15. Zhu Z., Sun Z.-Y., Ye Y., Voigt J., Strickland C., Smith E.M., Cumming J., Wang L., Wong J., Wang Y.-S., et al. Discovery of cyclic acylguanidines as highly potent and selective β-site amyloid cleaving enzyme (BACE) inhibitors. Part I. Inhibitor design and validation. J Med Chem 2010, 53:951-965.
16. May P.C., Dean R.A., Lowe S.L., Martenyi F., Sheehan S.M., Boggs L.N., Monk S.A., Mathes B.M., Mergott D.J., Watson B.M., et al. Central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci 2011, 31:6507-6516.
17. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274:1531-1534.
18. Kuo L. Fragment-based drug design: tools, practical approaches, and examples. Methods Enzymol 2011, 493:1-591.
19. Murray C., Verdonk M., Rees D. Experiences in fragment-based drug discovery. Trends Pharm Sci 2012, 33:224-232.
20. Erlanson D. Introduction to fragment-based drug discovery. Top Curr Chem 2012, 317:1-32.
21. Scott D., Coyne A., Hudson S., Abell C. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 2012, 51:4990-5003.
22. Kuglstatter A., Stahl M., Peters J., Huber W., Stihle M., Schlatter D., Benz J., Ruf A., Roth D., Enderle T., Hennig M. Tyramine fragment binding to BACE-1. Bioorg Med Chem Lett 2008, 18:1304-1307.
23. Efremov I.V., Vajdos F.F., Borzilleri K.A., Capetta S., Chen H., Dorff P.H., Dutra J.K., Goldstein S.W., Mansour M., McColl A., et al. Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design. J Med Chem 2012, 51:9069-9088.
24. Cheng Y., Judd T.C., Bartberger M.D., Brown J., Chen K., Fremeau R.T., Hickman D., Hitchcock S.A., Jordan B., Li V., et al. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). J Med Chem 2011, 54:5836-5857.
25. Geschwindner S., Olsson L.L., Albert J.S., Deinum J., Edwards P.D., de Beer T., Folmer R.H. Discovery of a novel warhead against beta-secretase through fragment-based lead generation. J Med Chem 2007, 50:5903-5911.
26. 19F NMR spectroscopy. J Med Chem 2012, 55:678-687.
27. Gerritz S.W., Zhai W., Shi S., Zhu S., Toyn J.H., Meredith J.E., Iben L.G., Burton C.R., Albright C.F., Good A.C., et al. Acyl guanidine inhibitors of β-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis. J Med Chem 2012, 55:9208-9223.
28. Yang W., Fucini R.V., Fahr B.T., Randal M., Lind K.E., Lam M.B., Lu W., Lu Y., Cary D.R., Romanowski M.J., et al. Fragment-based discovery of nonpeptidic BACE-1 inhibitors using tethering. Biochemistry 2009, 48:4488-4496.
29. Monceaux C., Hirata-Fukae C., Lam P., Totrov M., Matsuoka Y., Carlier P. Triazole-linked reduced amide isosteres: an approach for the fragment-based drug discovery of anti-Alzheimer's BACE1 inhibitors. Bioorg Med Chem Lett 2011, 21:3992-3996.
30. Madden J., Dod J.R., Godemann R., Kraemer J., Smith M., Biniszkiewicz M., Hallett D.J., Barker J., Dyekjaer J.D., Hesterkamp T. Fragment-based discovery and optimization of BACE1 inhibitors. Biorg Med Chem Lett 2010, 20:5329-5333.
31. Oefner C., Binggeli A., Breu V., Bur D., Clozel J.P., D'Arcy A., Dorn A., Fischli W., Grüninger F., Güller R., et al. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?. Chem Biol 1999, 6:127-131.
32. Zhu Z, McKittrick B, Sun Z-Y, Ye YC, Voigt JH, Strickland C, Smith EM, Stamford A, Greenlee WJ, Wu Y, et al.: Preparation of heterocyclic aspartyl protease inhibitors for treating various diseases. PCT Int Appl 2005, WO2005058311A1 20050630.
33. Stamford A.W., Scott J.D., Li S.W., Babu S., Tadesse D., Hunter R., Wu Y., Misiaszek J., Cumming J.N., Gilbert E., et al. Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS Aβ reduction. ACS Med Chem Lett 2012, 3:897-902.
34. Nowak P., Cole D.C., Aulabaugh A., Bard J., Chopra R., Cowling R., Fan K.Y., Hu B., Jacobsen S., Jani M., et al. Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent β-secretase (BACE1) inhibitors. Bioorg Med Chem Lett 2010, 20:632-635.
35. Kobayashi N, Kazuo U, Itoh N, Suzuki S, Sakaguchi G, Kato A, Yukimasa A, Hori A, Koriyama Y, Haraguchi H et al.: Preparation of 2-aminodihydrothiazine derivatives as β-secretase inhibitors. PCT Int Appl 2007, WO2007049532A1 20070503.
36. Hopkins A.L., Groom C.R., Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004, 9:430-431.
37. Wager T.T., Chandrasekaran R.Y., Hou X., Troutman M.D., Verhoest P.R., Villalobos A., Will Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci 2010, 1:420-434.
38. Cumming J.N., Smith E.M., Wang L., Misiaszek J., Durkin J., Pan J., Iserloh U., Wu Y., Zhu Z., Strickland C., et al. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. Bioorg Med Chem Lett 2012, 22:2444-2449.
39. Mandal M., Zhu Z., Cumming J.N., Liu X., Strickland S., Mazzola R.D., Caldwell J.P., Leach P., Grzelak M., Hyde L., et al. Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation. J Med Chem 2012, 55:9331-9345.
40. Swahn B.-M., Holenz J., Kihlstrom J., Kolmodin K., Lindstrom J., Plobeck N., Rottici D., Sehgelmeble F., Sundstrom M., von Berg S., et al. Aminoimidazoles as BACE-1 inhibitors: the challenge to achieve in vivo brain efficacy. Bioorg Med Chem Lett 2012, 22:1854-1859.
41. Gravenfors Y., Viklund J., Blid J., Ginman T., Karlstrom S., Kihlstrom J., Kolmodin K., Lindstrom J., von Berg S., von Kierseritzky F., et al. New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in brain. J Med Chem 2012, 55:9297-9311.
42. Swahn B.-M., Kolmodin K., Karlstrom S., von Berg S., Soderman P., Holenz J., Berg S., Lindstrom J., Sundstrom M., Turek D., et al. Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides. J Med Chem 2012, 55:9346-9361.
43. Malamas M., Erdei J., Gunawan I., Barnes K., Johnson M., Hui Y., Turner J., Hu Y., Wagner E., Fan K., et al. Aminoimidazoles as potent and selective human β-secretase (BACE1) inhibitors. J Med Chem 2009, 52:6314-6323.
44. Jeppsson F., Eketjäll S., Janson J., Karlström S., Gustavsson S., Olsson L.-L., Radesäter A.-C., Ploeger B., Cebers G., Kolmodin K., et al. Discovery of AZD3839, a potent and selective BACE1 clinical candidate for the treatment of Alzheimer's disease. J Biol Chem 2012, 287:41245-41257.
45. Congreve M., Aharony D., Albert J., Callaghan O., Campbell J., Carr R.A.E., Chessari G., Cowan S., Edwards P.D., Fredrickson M., et al. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of β-secretase. J Med Chem 2007, 50:1124-1132.
46. Dineen T.A., Weiss M.M., Williamson T., Acton P., Babu-Khan S., Bartberger M.D., Brown J., Chen K., Cheng Y., Citron M., et al. Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J Med Chem 2012, 55:9025-9044.
47. Hong L., Koelsch G., Lin X., Wu S., Terzyan S., Ghosh A.K., Zhang X.C., Tang J. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 2000, 290:150-153.
48. Charrier N., Clarke B., Cutler L., Demont E., Dingwall C., Dunsdon R., Hawkins J., Howes C., Hubbard J., Hussain I., et al. Second generation of BACE-1 inhibitors. Part 1. The need for improved pharmacokinetics. Bioorg Med Chem Lett 2009, 19:3664-3668.
49. Wu Y.J., Zhang Y., Good A.C., Burton C.R., Toyn J.H., Albright C.F., Macor J.E., Thompson L.A. Synthesis and SAR of hydroxyethylamine based phenylcarboxyamides as inhibitors of BACE. Bioorg Med Chem Lett 2009, 19:2654-2660.
50. Truong A.P., Tóth G., Probst G.D., Sealy J.M., Bowers S., Wone D.W., Dressen D., Hom R.K., Konradi A.W., Sham H.L., et al. Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett 2010, 20:6231-6236.